Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Genmab Analyst Ratings and Price Targets | NASDAQ:GMAB | Benzinga
Genmab AS has a consensus price target of $37.33 based on the ratings of 12 analysts. The high is $48 issued by BMO Capital on November 8, 2024. The low is $27 issued by Leerink Partners on February 13, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and Leerink Partners on April 9, 2025, March 11, 2025, and February 13, 2025, respectively. With an average price target of $36.33 between HC Wainwright & Co., Truist Securities, and Leerink Partners, there's an implied 76.85% upside for Genmab AS from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Truist Securities
Leerink Partners
BMO Capital
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Genmab
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 80.09% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $37 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2025 | Buy Now | 119.03% | Truist Securities | Asthika Goonewardene43% | $50 → $45 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | — | William Blair | Matt Phipps25% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 02/13/2025 | Buy Now | 31.42% | Leerink Partners | Jonathan Chang38% | → $27 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/23/2025 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 133.63% | BMO Capital | Etzer Darout49% | $46 → $48 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 50.89% | Morgan Stanley | Vikram Purohit39% | $31 → $31 | Maintains | Equal-Weight | Get Alert |
| 09/09/2024 | Buy Now | 143.37% | Truist Securities | Asthika Goonewardene43% | $53 → $50 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 50.89% | Morgan Stanley | Vikram Purohit39% | → $31 | Reinstates | → Equal-Weight | Get Alert |
| 08/27/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | — | JP Morgan | James Gordon65% | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/09/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/15/2024 | Buy Now | — | RBC Capital | Alistair Campbell7% | — | Upgrade | Sector Perform → Outperform | Get Alert |
| 06/27/2024 | Buy Now | 128.77% | BTIG | Kaveri Pohlman26% | $46 → $47 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 157.97% | Truist Securities | Asthika Goonewardene43% | $50 → $53 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 55.76% | Morgan Stanley | Matthew Harrison60% | $32 → $32 | Maintains | Underweight | Get Alert |
| 03/26/2024 | Buy Now | 143.37% | Truist Securities | Asthika Goonewardene43% | $50 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 133.63% | BMO Capital | Etzer Darout49% | $46 → $48 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2024 | Buy Now | 143.37% | Truist Securities | Asthika Goonewardene43% | $54 → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2024 | Buy Now | 143.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $49 → $50 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 138.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 138.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 55.76% | Morgan Stanley | Matthew Harrison60% | $33 → $32 | Maintains | Underweight | Get Alert |
| 11/08/2023 | Buy Now | 138.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $51 → $49 | Maintains | Buy | Get Alert |
| 10/18/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 10/13/2023 | Buy Now | 123.9% | BTIG | Kaveri Pohlman26% | $44 → $46 | Maintains | Buy | Get Alert |
| 09/26/2023 | Buy Now | 162.84% | Truist Securities | Asthika Goonewardene43% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | Buy Now | 162.84% | Truist Securities | Asthika Goonewardene43% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/24/2023 | Buy Now | 114.16% | BTIG | Kaveri Pohlman26% | → $44 | Initiates | → Buy | Get Alert |
| 08/15/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 08/04/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/31/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/31/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/17/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/11/2023 | Buy Now | 162.84% | Truist Securities | Asthika Goonewardene43% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 06/26/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | → $33 | Reiterates | → Underweight | Get Alert |
| 06/14/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | → $33 | Reiterates | → Underweight | Get Alert |
| 06/06/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | $47 → $51 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | 128.77% | HC Wainwright & Co. | Raghuram Selvaraju44% | $46 → $47 | Maintains | Buy | Get Alert |
| 04/20/2023 | Buy Now | 123.9% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $46 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 123.9% | HC Wainwright & Co. | Raghuram Selvaraju44% | $51 → $46 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 60.62% | Morgan Stanley | Matthew Harrison60% | $34 → $33 | Maintains | Underweight | Get Alert |
| 02/23/2023 | Buy Now | 65.49% | Morgan Stanley | Matthew Harrison60% | $35 → $34 | Maintains | Underweight | Get Alert |
| 02/06/2023 | Buy Now | 75.23% | SVB Leerink | — | $33 → $36 | Maintains | Market Perform | Get Alert |
| 01/24/2023 | Buy Now | 70.36% | Morgan Stanley | Matthew Harrison60% | $34 → $35 | Maintains | Underweight | Get Alert |
| 11/14/2022 | Buy Now | — | William Blair | Matt Phipps25% | — | Initiates | → Market Perform | Get Alert |
| 11/14/2022 | Buy Now | 65.49% | Morgan Stanley | Matthew Harrison60% | $31 → $34 | Maintains | Underweight | Get Alert |
| 11/10/2022 | Buy Now | 60.62% | SVB Leerink | Jonathan Chang38% | $31 → $33 | Maintains | Market Perform | Get Alert |
| 08/22/2022 | Buy Now | 148.24% | HC Wainwright & Co. | Raghuram Selvaraju44% | $49 → $51 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | 50.89% | Morgan Stanley | Matthew Harrison60% | $29 → $31 | Maintains | Underweight | Get Alert |
| 08/11/2022 | Buy Now | 50.89% | SVB Leerink | Jonathan Chang38% | $30 → $31 | Maintains | Market Perform | Get Alert |
| 07/20/2022 | Buy Now | 138.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $47 → $49 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Genmab (GMAB) stock?
The latest price target for Genmab (NASDAQ:GMAB) was reported by HC Wainwright & Co. on April 9, 2025. The analyst firm set a price target for $37.00 expecting GMAB to rise to within 12 months (a possible 80.09% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Genmab (GMAB)?
The latest analyst rating for Genmab (NASDAQ:GMAB) was provided by HC Wainwright & Co., and Genmab reiterated their buy rating.
When was the last upgrade for Genmab (GMAB)?
The last upgrade for Genmab AS happened on March 11, 2025 when William Blair raised their price target to N/A. William Blair previously had a market perform for Genmab AS.
When was the last downgrade for Genmab (GMAB)?
The last downgrade for Genmab AS happened on August 20, 2024 when JP Morgan changed their price target from N/A to N/A for Genmab AS.
When is the next analyst rating going to be posted or updated for Genmab (GMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Genmab (GMAB) correct?
While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $50.00 to $37.00. The current price Genmab (GMAB) is trading at is $20.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
